Key stats
- Market cap
- 3.44B
- Open
- —
- Day range
- —
- 52-week range
- $23.82 – $43.15
- Volume
- 13.5K
- Avg volume
- 5.09M
Q3 FY26Miss
Expected$-1.09
Actual$-1.55
VKTX
Viking Therapeutics Inc$27.01+$0.18+0.66%Price as of Nov 3, 2026, 9:28 AM ET
Earnings
Q2 FY26
Actual$-1.10
Q1 FY26
Actual$-1.37
Q4 FY25
Actual$-1.38
About
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
- Employees
- 65
- Headquarters
- San Diego, CA